Lindsay Berry

Statistical Scientist at Berry Consultants. Statistics PhD, Duke University.

[Lindsay Berry @LindsayBerry_]

A great example of when "an uninformative prior is actually very informative".

[Kert Viele @KertViele]

(1/n) New blog post from my colleague Joe Marion on prior distributions in CRMs. While we often discuss the “what” in design, Joe focuses on the equally important question of “how”, focusing on the information limited space of phase 1 trials.
https://t.co/Chkx68Btez

[Kert Viele @KertViele]

(1/n) New blog on using external/synthetic control data in a clinical trial. Quite late response to earlier discussions @leticiakawano. Includes thoughts on when/how to use external data, and usual arguments made in a regulatory setting. Quick summary….
https://t.co/NbKCSLU2aZ

[Lindsay Berry @LindsayBerry_]

@RWJE_BA @JasonConnorPhD @KertViele @martabofillr @GoldLabCharite @KH_Stats @FraKoenig @DominicMagirr @posch_m @imi_eupearl Roig et al's results don't support blanket statement that nonconcurrent=bad. Concurrent can be less efficient. If there are time-treatment interactions, concurrent may be better but there's a question of if results are applicable to future patients if disease changes so much.

[Colin Begg @ColinBBegg]

Ben Saville and colleagues propose modeling of temporal drift to account for time effects when analyzing platform trials. @Stats_Ninja_ @SCTorg @BerryConsultant @statberry @KertViele @berryni
https://t.co/5NPMJPG7X8

[Berry Consultants @BerryConsultant]

Berry Consultants Acquires ADDPLAN® Clinical Trial Simulation Software from ICON - https://t.co/yeQ3todZBy

[Dan Rogland @DanRogland]

This is horrifying, and I’m going to thread resources below about how you can help in this situation and/or what resources you can use if you’re an affirming parent or educator in Texas right now

[Berry Consultants @BerryConsultant]

@statberry and @kertviele will be speaking at the @imi_eupearl webinar on non-concurrent controls in platform trials on 2/24/22. They and others will discuss with external stakeholders when and how to utilise non-concurrent control data in platform trials. https://t.co/UbGUAjCgOS

[remap-cap @remap_cap]

Patient number 10,000 has been randomized today at @BarwonHealth as part of the REMAP-CAP trial. What a great achievement! By contributing to research, patients are not only caring for themselves, but also for future patients.🙌
#remapcapfamily #globalresearch #whywedoresearch

[Global Coalition for Adaptive Research @GCAResearch]

To kick off our GBM AGILE Spotlight series, we are delighted to present Don Berry, Lead Statistician of #GBMAGILE and Founder, @BerryConsultant
It's imperative that clinical trials keep pace with science. Learn how GBM AGILE is paving the way for more innovative research.

[Lindsay Berry @LindsayBerry_]

@KertViele @raj_mehta Confirmed -- all randomization of TAC and usual care was concurrent in the mpRCT!

[Lindsay Berry @LindsayBerry_]

@ADAlthousePhD @f_g_zampieri @drjohnm @djc795 @f2harrell @stephensenn @statberry @KertViele @brophyj @kaulcsmc @DrToddLee @PulmCrit 100% not a meta-analysis, it's a pre-specified RCT. Each trial reached hypothesis separately and then decided to harmonize analysis plan, design, and pool data to get an answer more quickly. Decision to combine was made before any analyses were conducted, all pre-specified

[Lindsay Berry @LindsayBerry_]

@drjohnm @ADAlthousePhD @f2harrell @stephensenn @statberry @KertViele @brophyj @kaulcsmc @djc795 Paper discussion says TAC "would be anticipated to result in the survival of 40 additional patients until hospital discharge without organ support at the expense of 7 additional major bleeding events". Does that help interpret OR point estimate?

[Lindsay Berry @LindsayBerry_]

@cpgale3 @drjohnm @DrToddLee @f2harrell @stephensenn @statberry @ADAlthousePhD @KertViele Trial designed for a pandemic when sample size, enrollment, design unknown. Bayesian + adaptive trial most suitable in this setting. Bayes remains interpretable if trial stopped early for external reasons (other trial release results)

[NEJM @NEJM]

In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. https://t.co/3JzKdmL3SB #IDTwitter

[NEJM @NEJM]

Anticoagulation did not improve hospital survival in critically Ill patients with #COVID19. https://t.co/E8RXE01jbF

[remap-cap @remap_cap]

Results of @remap_cap #Covid_19 #Antiviral Domain released Online First @yourICM: Among critically ill patients with COVID-19, #lopinavir-ritonavir, #HydroxyChloroquine, or combination therapy worsened outcomes compared to no antiviral therapy

[remap-cap @remap_cap]

For patients with #COVID19 receiving organ support in the ICU, #antiplatelet therapy with aspirin or P2Y12 inhibitor (which were found to be equivalent), was ineffective at improving death and organ support free days when compared to no #antiplatelet therapy. 1/8

[ATTACC CAP @ATTACC_CAP]

The pre-print of the ATTACC, @ACTIV4a, and @remap_cap mpRCt Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 is now available at https://t.co/DqKrYjgbpX

[Kert Viele @KertViele]

For those "at" SCT2021...plug for my colleagues. Wonderful Bayesian session where every presentation has made national/international news (LA COVID modeling, PRINCIPLE, @remap_cap , and the Pfizer vaccine trial). @lindsrberry @Stats_Ninja_ @RogerJLewis

2:00pm EST 5/18